Quasi-Drugs Report The Regulated Cosmeceuticals & Growing Market
Quasi-Drugs Report: The Regulated Cosmeceuticals with Growing Market

The report will include the approvals of quasi-drugs from regulatory organizations, market research, and the competitive aspect of Quasi-drugs. Special emphasis is given to the regulatory approvals in Japan and other countries in Asia pacific regions. Under the Pharmaceutical and…

Read More
Ranbaxy at back foot: Punjab’s plant (4th in India) banned by FDA

Ranbaxy Laboratories which is one of the largest and reputed companies of India, exports its drugs throughout the world. U.S. is the main consumer of generic drugs made at Ranbaxy but due to one defect found in the drugs of…

Read More
Efavirenz (HIV Drug) case: Bristol (BMS) won over Mylan Pharma

Bristol Meyers Squibb (BMS), manufacturers of Efavirenz (patented drug for HIV) won over the companies named Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd. that made generic version of Efavirenz that is Sustiva. The companies filed an application in court for…

Read More
Pharmaceutical Companies shift from Small Molecule Drugs to Biotech Drugs

Recently, the Tufts University’s Center for the Study of Drug Development (CSDD) released an interesting report revealing the dramatic shift of pharmaceutical companies from manufacturing small molecule drugs to a large number of biotechnology drugs. The report shows that in…

Read More
ViaCyte: Regenerative Medicine and Cell Therapy Derived from Stem Cells

ViaCyte Inc. is emerging as a leader in regenerative medicine and is all set to develop a new approach for the treatment of major diseases using cell therapy derived from stem cells. The company was granted 28 patents in 2011-2013…

Read More
Important Drug Patents to Expire in 2014 for Generic Production

Year 2014 would be a big loss year for the Pharma companies because of the expiry of patents granted for some of the major medicines. It is estimated that due to the loss of IP protection, sales worth $34 billion…

Read More
Unaffordable Life Saving Drug (Linezolid by Pfizer) Leaves TB Patients Struggling in South Africa

South Africa could not keep up with the treatment for Drug resistant Tuberculosis (TB), which has affected thousands of people in the country. Many of the sufferers would die and the death would be horrible and slow. Not only this,…

Read More
‘Fire In the Blood’ – An Eye Opener for Patent Law Makers in Pharmaceuticals

Fire in the Blood, is a documentary on “medicine, monopoly and malice.” It tells the story of how Western pharmaceutical companies and governments blocked access to low-cost AIDS drugs for the countries of the global south in the years after…

Read More
Patent on Method of Cellular Differentiation Granted to Cellular Dynamics International (CDI)

CDI (Cellular Dynamics International), a leader in developing induced pluripotent stem cell technologies for in vitro drug development, in vivo cellular therapeutic research and stem cell banking was granted patent no. US8557580 on October 15, 2013 entitled “Methods and Compositions…

Read More
Indian Pharma Landscape: Growing Presence in International Market

Indian pharmaceutical companies have increased their expenditure in their research and development section by 19.7%. The purpose of this increment is not to discover new drugs but to create more cost effective generic drugs. More investment may make them a…

Read More
Victory of Generic Companies: Benefit to Consumers

Conflicts between the innovators and generic companies have increased to a great extent and the latest example of the same is the one between Novartis and Merck-Glenmark. These conflicts came into picture when Mylan filed an Abbreviated New Drug Application…

Read More